Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Anlotinib + Furmonertinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Anlotinib | AL3818|AL-3818|AL 3818 | FGFR Inhibitor (Pan) 26 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 53 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, FGFR1-4, PDGFRA/B, KIT, and RET, which may inhibit angiogenesis and tumor cell growth (PMID: 27716285, PMID: 32547218, PMID: 32724339). | |
| Furmonertinib | AST2818|AST2818|Alflutinib|firmonertinib | EGFR Inhibitor 3rd gen 28 | Furmonertinib (alflutinib) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (PMID: 33780662, PMID: 35662408). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|